ACCESS-AD: a new European initiative to accelerate timely and equitable AD diagnosis, treatment and care

Today

2026-01-13

(Press-News.org)

Amsterdam, 13 January 2026. Today, the ACCESS-AD consortium is announcing the launch of a transformative European initiative that will accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems. The international consortium - bringing together academic institutions, industry partners, SMEs and patient organisations - is co-led by Amsterdam UMC, Siemens Healthineers, King’s College London and Gates Ventures, with funding from the European Commission’s Innovative Health Initiative for a five-year period.

The project begins at a pivotal moment for AD care in Europe. In 2025, two new disease-modifying therapies (DMTs), lecanemab and donanemab, received regulatory approval, offering a first opportunity to slow the progression of AD. However, additional accessible and scalable treatment options are also needed, since Member States are confronted with rapidly escalating diagnostic bottlenecks, long waiting times and a growing shortage of specialised healthcare professionals. AD prevalence is rising sharply and is expected to exceed 19 million by 2050 in Europe alone. Health systems are already struggling to deliver timely diagnostic testing, brain imaging and structured clinical follow-up, raising the risk of delayed treatment and poorer outcomes.

ACCESS-AD aims to address these challenges directly, accelerating innovation and strengthening equitable access to timely and effective care. “Our vision is simple but ambitious: to make personalised care a reality for every patient with AD, regardless of where they live,” said Professor Frederik Barkhof from Amsterdam UMC and Clinical Lead of ACCESS-AD. “ACCESS-AD brings together the clinical, scientific and societal stakeholders needed to turn innovation into everyday practice across Europe.”

A Europe-wide, integrated framework for diagnosis, treatment and monitoring

ACCESS-AD is pioneering a coordinated, multimodal clinical framework that unites brain imaging, blood-based biomarkers, digital monitoring tools, AI-driven decision support, and real-world evidence into a seamless patient pathway. Its design aims to accelerate diagnostic confirmation, support the safe administration of DMTs and novel interventions, and broaden access to advanced innovations beyond specialist centres, including primary care and underserved regions.

A central focus of the project is the combination of advanced but accessible neuroimaging with expanded use of fluid and digital biomarkers. This will support early and accurate patient identification, enabling timely diagnosis and entry into personalised treatment pathways that may include DMTs, targeted lifestyle interventions and nutritional strategies. ACCESS-AD also aims to widen access to tools that historically have been available only in centres of excellence, such as accelerated MRI protocols, quantitative amyloid PET and automated safety monitoring.

ACCESS-AD introduces a coordinated innovation pathway structured across four key clinical stages:

DETECT: integration of blood-based biomarkers and digital tools with accelerated MRI and quantitative PET for scalable diagnostic confirmation STRATIFY: patient-centred workflows informed by AI-based progression and treatment-response models, advancing precision medicine in AD TREAT: real-world data collection on the usability, safety and implementation of DMTs and lifestyle interventions across multiple European settings MONITOR: AI and digital tools for continuous monitoring of disease progression, supported by brain imaging protocols optimised for DMT safety monitoring

“ACCESS-AD brings together expertise from across Europe to address the urgent need for more effective and personalised Alzheimer’s care,” said Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers, Industry Lead of ACCESS-AD. “By integrating laboratory diagnostics, advanced imaging, and AI-driven digital tools, this coordinated approach aims to strengthen the entire care pathway – enabling timely diagnosis, precision treatment, and equitable access to innovations across diverse care settings.”

AI-driven prediction to guide safety and treatment decisions

The ACCESS-AD framework is being built around AI-driven prediction models capable of forecasting treatment response, identifying patients at risk of adverse events, and guiding personalised treatment planning. These models will draw upon harmonised MRI and PET data, blood biomarkers and digital measures from wearables and smartphones. A dementia dashboard will synthesise the multimodal data into clear, actionable insights for clinicians in both specialist and community-based settings.

“Sharing and integrating diverse data sources is essential to build robust AI models that can identify the right patients, for the right treatment, at the right time,” said Niranjan Bose, Industry Co-Lead from Gates Ventures. “ACCESS-AD will demonstrate how responsible data ecosystems can accelerate both scientific discovery and clinical impact.”

Real-world evidence to strengthen European system preparedness

A cornerstone of ACCESS-AD is its pan-European AD registry, which will leverage the established InRAD platform. This infrastructure will collect real-world data from more than 500 patients across a variety of health systems, capturing safety, clinical evolution and treatment outcomes under routine clinical conditions. The registry will also support a pilot study that tests the feasibility of combining DMTs with a multicomponent lifestyle intervention and advanced nutritional supplements from Nestlé, as well as a clinical prediction study of the once-daily oral therapy, blarcamesine.

Recognising the need for equitable and scalable implementation, ACCESS-AD integrates health-economic modelling, regulatory development, ethical reflection and sustainability assessments. European Patient Advisory Boards will ensure that the needs and values of patients and carers are embedded throughout the project. ACCESS-AD builds on other IHI initiatives including PROMINENT, PREDICTOM, AD-RIDDLE and EPND, ensuring that advances in early detection, biomarker innovation and data infrastructure translate into improved diagnosis, treatment and care.

“ACCESS-AD is a holistic effort across private and public sectors,” noted Professor Dag Aarsland from KCL, clinical co-Lead of the project. “By combining technological innovation with economic, ethical, regulatory and patient perspectives, we aim to chart a sustainable, scalable and equitable pathway for the implementation of new AD diagnostics and treatments, including multidomain lifestyle interventions and new disease-modifying therapies.”

About ACCESS-AD

ACCESS-AD receives funding under the auspices of the Innovative Health Initiative Joint Undertaking (IHI JU). The ACCESS-AD programme has an initial budget of over €37 million, comprising ca. €20 million from the EU and ca. €17 million from the industry partners. The budget is distributed across the following 30 partners:

Stichting Amsterdam UMC Siemens Healthineers AG King’s College London Gates Ventures LLC Alzheimer Europe Anavex Germany GmbH Amsterdam UMC Research BV Deutsches Zentrum für Neurodegenerative Erkrankungen EV Eisai Limited Ethniko Kentro Erevnas Kai Technologikis Anaptyxis Fakultni Nemocnice v Motole Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung EG Fundacio de Recerca Clinic Barcelona – Institut d’Investigacions biomediques August pi Sunyer Helse Stavanger HF Hospital Clinic de Barcelona InRAD - Stichting International Registry for Alzheimer’s Disease and other Dementias Karolinska Institutet Klinikum der Ludwig-Maximilians Universität München Ludwig-Maximilians Universität München Muhdo Health Ltd National Institute for Health and Care Excellence Neotiv GmbH Neurimmune SubOne AG Pohjois-Savon Hyvinvointialue Positrigo AG Region Stockholm Siemens Healthcare Diagnostics Products GmbH Siemens Healthcare Limited Siemens Healthcare Private Ltd Siemens Healthcare SL Siemens Healthineers International AG Societé de Produits Nestlé SA Universidad de Navarra Universitätsklinikum Erlangen University College London University of Leicester

To learn more about ACCESS-AD, visit the project website: www.access-ad.org

For additional information, please contact info@access-ad.org

About the Innovative Health Initiative

The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health, and vaccine industries, namely COCIR, EFPIA (including Vaccines Europe), EuropaBio, and MedTech Europe. IHI’s total budget for the period 2021-2027 is €2.4 billion. Half of this comes from Horizon Europe, the EU’s research and innovation programme. The IHI industry partners have committed €1 billion to IHI, and a further €200 million can be committed by other organisations that decide to become Contributing Partners.

Acknowledgement

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101253010. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe, and Anavex, Muhdo and Neurimmune.

Disclaimer

ACCESS-AD is funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. None of the aforementioned parties can be held responsible for them.

END

ELSE PRESS RELEASES FROM THIS DATE:

Mercury exposure in northern communities linked to eating waterfowl

2026-01-13

A new study led by researchers at the University of Waterloo found that members of many Indigenous communities who eat certain types of locally harvested waterfowl, especially ducks with mixed or fish-based diets, may have higher levels of both mercury and healthy omega-3 fatty acids in their blood. The research, conducted in partnership with northern First Nations communities, suggests that waterfowl, such as ducks and geese, may need to be included more regularly in monitoring programs that track both contaminants and nutrients in traditional foods. “Traditional foods ...

New Zealand researchers identify brain link to high blood pressure

2026-01-13

Scientists have discovered that a part of the brain may be behind high blood pressure. The lateral parafacial region sits in the brainstem – the oldest part of the brain – which controls automatic functions such as digestion, breathing, and heart rate. “The lateral parafacial region is recruited into action causing us to exhale during a laugh, exercise or coughing,” says lead researcher Professor Julian Paton, director of Manaaki Manawa, Centre for Heart Research at Waipapa Taumata Rau, University of Auckland. “These ...

New research confirms people with ME/CFS have a consistent faulty cellular structure

2026-01-13

A faulty ion channel function is a consistent biological feature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), providing long-awaited validation for hundreds of thousands of Australians living with the debilitating illness. The new Griffith University research found a crucial cellular structure responsible for calcium transport, the TRPM3 ion channel, was faulty in immune cells from people with ME/CFS. Director and senior author, Professor Sonya Marshall-Gradisnik from Griffith’s National Centre for Neuroimmunology and Emerging Diseases (NCNED), said the TRPM3 played an essential role in calcium transport into cells, regulating responses properly ...

Hidden cancer risk behind fatty liver disease targets

2026-01-13

Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead increase the risk of chronic liver damage and cancer as we age. In a major new study published in Science Advances, researchers from Adelaide University have shown that loss of the enzyme Caspase-2 drives abnormal growth in liver cells, triggering inflammation, fibrosis, and a significantly higher risk of liver cancer. The findings challenge growing interest in Caspase-2 inhibitors as a potential therapeutic strategy to treat and/or prevent fatty liver disease and highlight the need for caution when targeting this ...

Born in brightness, leading to darkness

2026-01-13

Kyoto, Japan -- What we know of the birth of a black hole has traditionally aligned with our perception of black holes themselves: dark, mysterious, and eerily quiet, despite their mass and influence. Stellar-mass black holes are born from the final gravitational collapse of massive stars several tens of the mass of our Sun which, unlike less massive stars, do not produce bright, supernova explosions. Or at least, this is what astronomers had previously thought, because no one had observed in real time the collapse of a massive star leading to a supernova and forming a black hole. That is, until a team of researchers at Kyoto University reported their observations of SN 2022esa. The ...

Boron-containing Z-type and bilayer benzoxene

2026-01-13

The research group of Professor Chuandong Dou at the State Key Laboratory of Supramolecular Structure and Materials, Jilin University, recently constructed two novel boron-hexane two-dimensional benzobenzenes using a borane-controlled cyclization strategy, elucidating the importance of boron atom doping. Using conjugated boranes as precursors, the researchers synthesized boron-hexane Z-type and bilayer benzobenzenes C32B2 via FeCl3 and Bi(OTf)3-mediated intramolecular cyclization reactions, obtaining narrow-spectrum fluorescence (half-width at half-maximum as narrow as 19 nm) and amplified spontaneous emission properties, demonstrating their ...

Hong Kong researchers break the single-field barrier with dual-field assisted diamond cutting

2026-01-13

A team at The Hong Kong Polytechnic University has created a machining method that takes a clear step beyond all existing field-assisted cutting techniques. Instead of using only one external energy field, such as heat or magnetism, the new approach applies a laser field and a magnetic field at the same time during diamond cutting. This dual-field method offers a way to machine advanced materials that are extremely difficult to process with conventional techniques. Field-assisted machining has been used for years to support precision manufacturing. But these traditional methods rely on just one type of assistance, which increasingly falls short as ...

Work hard, play hard?

2026-01-13

As Australians return to work after the holidays, many will be reflecting on their health and wellbeing goals for the year ahead. New research led by Flinders University reveals that while workplace factors like long hours, work-related stress and shift work do influence high-risk drinking, personal and social factors play an even bigger role. The study, published in Drug and Alcohol Review journal, examined more than two decades of data from the national Household Income and Labour Dynamics in Australia (HILDA) survey to uncover how job-related factors influence alcohol consumption among workers. Lead author Dr Gianluca Di Censo from Flinders’ ...

Wood becomes smart glass: Photo- and electro-chromic membrane switches tint in seconds

2026-01-13

Transparent electronics usually start with indium-tin-oxide coated glass—expensive, brittle and anything but eco-friendly. A Chinese-led team has now turned ordinary basswood into a 65-micrometre membrane that behaves like smart glass yet folds like paper. Writing in the Journal of Bioresources and Bioproducts, they describe a two-step recipe: first remove lignin and oxidise the cellulose with TEMPO to create a nanofibre mesh; then hot-press and impregnate the sheet with PMMA to restore strength and push optical transmittance to 86 %. A light-sensitive skin comes from spin-coating a PMMA layer doped with WO₃ nanoparticles. When hit by sunlight or a 365 nm desk lamp, ...

The Lancet: COVID-19 vaccine hesitancy decreased over time, though mistrust persists among certain groups, study of over 1 million people in England suggests

2026-01-13

First study to link COVID-19 vaccine attitudes to subsequent (including post-pandemic) vaccination behaviour sheds light on barriers to future vaccination uptake. Findings reveal a general decline in vaccine hesitancy during the 15 months following the COVID-19 vaccine roll-out in 2021-2022, with almost two-thirds of those initially hesitant going on to receive one or more COVID-19 vaccinations. The most common reasons for original COVID-19 vaccine hesitancy were concerns around vaccine effectiveness and side ...

The Lancet: COVID-19 vaccine hesitancy decreased over time, though mistrust persists among certain groups, study of over 1 million people in England suggests

Nature Communications study from the Lundquist Institute identifies molecular mechanism underlying peripartum cardiomyopathy

Pennington Biomedical’s Dr. Gang Hu appointed to NIH Reproductive, Perinatal and Pediatric Health Review Group

World-first project shows great promise to treat low eye pressure

[Press-News.org] ACCESS-AD: a new European initiative to accelerate timely and equitable AD diagnosis, treatment and care
Today

ACCESS-AD: a new European initiative to accelerate timely and equitable AD diagnosis, treatment and care

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: